利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

6 条记录 (耗时 0.024 秒)

    Nr-CAM gene, nucleic acids and nucleic acid products for therapeutic and diagnostic uses for tumors
    2.
    发明申请
    Nr-CAM gene, nucleic acids and nucleic acid products for therapeutic and diagnostic uses for tumors 审中-公开
    Nr-CAM基因，用于肿瘤治疗和诊断用途的核酸和核酸产物

    公开(公告)号：US20060269558A1

    公开(公告)日：2006-11-30

    申请号：US11445961

    申请日：2006-06-01

    申请人： Gerald Murphy ,  Alton Boynton ,  Anil Sehgal ,  Bridget Murphy

    发明人： Gerald Murphy ,  Alton Boynton ,  Anil Sehgal ,  Bridget Murphy

    IPC分类号： C12Q1/68 ,  G01N33/574 ,  A61K39/395

    CPC分类号： G01N33/57407 ,  C12Q1/6886 ,  C12Q2600/136 ,  C12Q2600/158

    摘要： The present invention relates to the identification of a novel role of Nr-CAM in cell transformation and aberrant cellular proliferation. In particular, the present invention relates to the altered gene expression of Nr-CAM in a number of primary tumors and cell lines derived from tumors, in addition to, the altered gene expression of ligands for Nr-CAM. Further, the present invention relates, in part, to the Applicants' surprising discovery that the inhibition of Nr-CAM gene expression or the inhibition of Nr-CAM activity in transformed cells reverses the transformed phenotype.

    摘要翻译： 本发明涉及鉴定Nr-CAM在细胞转化和异常细胞增殖中的新作用。 特别地，本发明涉及Nr-CAM在许多原发肿瘤和衍生自肿瘤的细胞系中的改变的基因表达，以及用于Nr-CAM的配体的改变的基因表达。 此外，本发明部分地涉及申请人令人惊奇的发现，即Nr-CAM基因表达的抑制或转化细胞中Nr-CAM活性的抑制逆转转化的表型。

    Monoclonal antibody specific for the extracellular domain of prostate specific membrane antigen
    3.
    发明申请
    Monoclonal antibody specific for the extracellular domain of prostate specific membrane antigen 有权
    特异于前列腺特异性膜抗原细胞外结构域的单克隆抗体

    公开(公告)号：US20070128671A1

    公开(公告)日：2007-06-07

    申请号：US11150507

    申请日：2005-06-09

    申请人： Gerald Murphy ,  Alton Boynton ,  Eric Holmes ,  William Tino

    发明人： Gerald Murphy ,  Alton Boynton ,  Eric Holmes ,  William Tino

    IPC分类号： G01N33/574

    CPC分类号： C07K16/28 ,  A61K49/0058 ,  A61K51/1027 ,  A61K51/1072 ,  C07K16/3069 ,  C07K2317/34 ,  C12N2799/026 ,  G01N33/57434

    摘要： The present invention relates to monoclonal antibodies that bind to the extracellular domain of prostate-specific membrane antigen (PSMA), hybridoma cell lines producing the antibodies, and methods of using such antibodies for diagnosis and treatment of cancer. In particular, thirty-five monoclonal antibodies reactive with PSMA expressed on the cell surface are exemplified. Additionally, the present invention relates to a novel protein variant (PSM′) of PSMA detected by a number of the antibodies of the invention. The hydrolase activity of PSMA and PSM′ allows the use of an immunoenzymatic assay for their detection.

    摘要翻译： 本发明涉及结合前列腺特异性膜抗原（PSMA）的细胞外结构域的单克隆抗体，产生抗体的杂交瘤细胞系，以及使用这种抗体诊断和治疗癌症的方法。 特别地，示例了在细胞表面上表达的与PSMA反应的三十五种单克隆抗体。 另外，本发明涉及由本发明的许多抗体检测的PSMA的新型蛋白质变体（PSM'）。 PSMA和PSM'的水解酶活性允许使用免疫酶测定法进行检测。

    METHOD TO INCREASE CLASS I PRESENTATION OF EXOGENOUS ANTIGENS BY HUMAN DENDRITIC CELLS
    5.
    发明申请
    METHOD TO INCREASE CLASS I PRESENTATION OF EXOGENOUS ANTIGENS BY HUMAN DENDRITIC CELLS 审中-公开
    通过人类细胞增加外源性抗原的类别的方法

    公开(公告)号：US20080171023A1

    公开(公告)日：2008-07-17

    申请号：US11972565

    申请日：2008-01-10

    申请人： Michael Salgaller ,  Alton Boynton

    发明人： Michael Salgaller ,  Alton Boynton

    IPC分类号： A61K35/12 ,  C12N5/06 ,  A61P43/00

    CPC分类号： A61K39/0011 ,  A61K2039/5154 ,  A61K2039/5158

    摘要： Methods and compositions for use of human dendritic cells to activate T cells for immunotherapeutic responses against primary and metastatic cancer are disclosed. In one embodiment, human dendritic cells exposed to a tumor associated antigen, or an antigenic fragment thereof in combination with bacillus Calmette-Guerin (BCG), are administered to a cancer patient to activate a predominantly CD8+T cell response in vivo. In an alternate embodiment, human dendritic cells are exposed to a tumor associated antigen or a specific antigenic peptide in combination with BCG in vitro and incubated or cultured with primed or unprimed T cells to activate a predominantly CD8+T cell response in vitro. The activated T cells are then administered to a cancer patient. Antigen in combination with BCG is processed by dendritic cells through the MHC-CLASS I compartment which provides for a predominantly CD8+T cell response. The addition of LPS provides for a greater number of mature dendritic cells enhancing the T cell response to antigen. Methods and compositions for human dendritic cells with extended life span and cryopreserved dendritic cells are disclosed.

    摘要翻译： 公开了使用人树突状细胞激活T细胞用于针对原发性和转移性癌症的免疫治疗反应的方法和组合物。 在一个实施方案中，向癌症患者施用暴露于肿瘤相关抗原的人树突状细胞或其与抗原卡介苗（BCG）组合的抗原性片段，以激活主要的CD8 + 体内细胞反应。 在替代实施方案中，人体树突状细胞在体外暴露于与BCG组合的肿瘤相关抗原或特异性抗原肽，并与引发或未引发的T细胞一起孵育或培养以激活主要的CD8 + 体外细胞反应。 然后将活化的T细胞施用于癌症患者。 与BCG组合的抗原通过树突状细胞通过MHC-CLASS I室进行处理，其提供主要的CD8 + T细胞应答。 LPS的添加提供了更多数量的增强T细胞对抗原的响应的成熟树突状细胞。 公开了延长寿命的人树突状细胞和低温保存的树突状细胞的方法和组合物。